MX2010009959A - Compuestos y metodo para reducir el acido urico. - Google Patents

Compuestos y metodo para reducir el acido urico.

Info

Publication number
MX2010009959A
MX2010009959A MX2010009959A MX2010009959A MX2010009959A MX 2010009959 A MX2010009959 A MX 2010009959A MX 2010009959 A MX2010009959 A MX 2010009959A MX 2010009959 A MX2010009959 A MX 2010009959A MX 2010009959 A MX2010009959 A MX 2010009959A
Authority
MX
Mexico
Prior art keywords
hydrogen
carbon atoms
alkyl
uric acid
ring
Prior art date
Application number
MX2010009959A
Other languages
English (en)
Inventor
Shalini Sharma
Borstel Reid W Von
Michael K Bamat
Ramachandran Arudchandran
James Dennen O'neil
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of MX2010009959A publication Critical patent/MX2010009959A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/38—Sucrose-free products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A23G3/56—Products with edible or inedible supports, e.g. lollipops
    • A23G3/563—Products with edible or inedible supports, e.g. lollipops products with an inedible support, e.g. a stick
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

El ácido úrico en sujetos mamíferos se reduce y la excreción de ácido úrico se incrementa al administrar un compuesto de la Fórmula (I) o una sal farmacéuticamente aceptable del mismo. En la fórmula (I), m es 0, 1, 2, 3 o 4; n es 0 o 1; m+ n no es mayor que 4; t es 0 o 1; q es 0 o 1; y r es 0, 1 o 2. R6 es hidrógeno, metilo o etilo y R12 es hidrógeno o metilo, o R6 es hidroxi y R12 es hidrógeno, o R6 es O y R12 está ausente, o R6 y R12 juntos son -CH2CH2-. R7 es hidrógeno o alquilo que tiene de 1 a 3 átomos de carbono. Uno de R8 y R9 es alquilo que tiene de 1 a 3 átomos de carbono y el otro es hidrógeno o alquilo que tiene de 1 a 3 átomos de carbono. R10 es hidrógeno, halo, alquilo que tiene de 1 a 3 átomos de carbono o alcoxi que tiene de 1 a 3 átomos de carbono. X es C(O) y r es 0 y t es 0; o X es NH(R11) en donde R11 es hidrógeno o alquilo que tiene de 1 a 3 átomos de carbono. A es fenilo, no sustituido o sustituido por 1 o 2 grupos seleccionados de halo, hidroxi, metilo, etilo, perfluorometilo, metoxi, etoxi y perfluorometoxi; o un anillo heteroaromático de 5 o 6 miembros que tiene 1 o 2 heteroátomos del anillo seleccionados de N, S y O y el anillo heteroaromático se enlaza covalentemente al resto del compuesto de la Fórmula (I) por medio de un átomo de carbono del anillo; o cicloalquilo que tiene de 3 a 6 átomos de carbono del anillo en donde el grupo cicloalquilo no es sustituido o uno o dos átomos de carbono del anillo son inonosustituidos independientemente por metilo o etilo. Los efectos que disminuyen el ácido úrico de los Compuestos de la Fórmula (I) se utilizan para tratar o prevenir una variedad de condiciones que incluyen gota, hiperuricemia, niveles elevados de ácido úrico que no alcanzan los niveles que justifican usualmente una diagnosis de hiperuricemia, disfunción renal, cálculos renales, enfermedad cardiovascular, riesgo 'para desarrollar una enfermedad cardiovascular, síndrome de lisis tumoral y deterioro cognoscitivo.
MX2010009959A 2008-03-13 2009-03-13 Compuestos y metodo para reducir el acido urico. MX2010009959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3629408P 2008-03-13 2008-03-13
PCT/US2009/037128 WO2009151695A1 (en) 2008-03-13 2009-03-13 Compounds and method for reducing uric acid

Publications (1)

Publication Number Publication Date
MX2010009959A true MX2010009959A (es) 2010-10-04

Family

ID=41417026

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011790A MX342806B (es) 2008-03-13 2009-03-13 Compuestos y método para reducir el ácido úrico.
MX2010009959A MX2010009959A (es) 2008-03-13 2009-03-13 Compuestos y metodo para reducir el acido urico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013011790A MX342806B (es) 2008-03-13 2009-03-13 Compuestos y método para reducir el ácido úrico.

Country Status (17)

Country Link
US (2) US8829058B2 (es)
EP (2) EP2268141B1 (es)
JP (2) JP5339545B2 (es)
KR (2) KR101677945B1 (es)
CN (2) CN101969773B (es)
AU (1) AU2009258040B8 (es)
BR (2) BRPI0924547B1 (es)
CA (1) CA2716860C (es)
DK (1) DK2268141T3 (es)
ES (1) ES2741153T3 (es)
IL (2) IL208004A (es)
MX (2) MX342806B (es)
NZ (2) NZ602321A (es)
RU (2) RU2501555C2 (es)
UA (2) UA103894C2 (es)
WO (1) WO2009151695A1 (es)
ZA (1) ZA201005872B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969773B (zh) 2008-03-13 2015-08-19 维尔斯达医疗公司 用于降低尿酸的化合物和方法
US8410154B2 (en) 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
WO2012102405A1 (ja) 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
WO2012125533A1 (en) * 2011-03-14 2012-09-20 Wellstat Therapeutics Corporation 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
KR20150002799A (ko) * 2012-04-13 2015-01-07 사이머베이 쎄라퓨틱스, 인코퍼레이티드 할로페네이트 또는 할로펜산 및 소염제를 이용한 통풍 환자에서의 고요산혈증 치료 방법
EP2878594B1 (en) 2012-07-27 2018-11-28 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
WO2017083652A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York Fluorenone compound for the treatment of gout
CN106190953B (zh) * 2016-07-25 2019-12-10 华南理工大学 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用
CN106190954B (zh) * 2016-07-25 2019-12-10 华南理工大学 一种高尿酸血症肝细胞模型及其构建方法
KR101988867B1 (ko) 2017-07-25 2019-06-13 광주과학기술원 금 나노입자를 이용한 요산 분해용 조성물
WO2019066469A1 (ko) * 2017-09-27 2019-04-04 경북대학교 산학협력단 페북소스타트 또는 토피록소스타트의 암 전이의 예방 및 치료제로서의 용도
WO2021194294A1 (ko) * 2020-03-27 2021-09-30 가톨릭대학교 산학협력단 자가면역질환 평가 아바타 모델 플랫폼

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572512B1 (fr) 1984-10-25 1987-09-25 Luchaire Sa Dispositif, adaptable sur engins ou munitions, tels que projectiles d'artillerie, destine a reduire leur trainee de culot
DE3884825D1 (de) 1987-02-16 1993-11-18 Konishiroku Photo Ind Entwickler für lichtempfindliche lithographische Druckplatte, gemeinschaftlich verarbeitungsfähig für den Negativ-Typ und den Positiv-Typ und Entwicklerzusammensetzung für lichtempfindliches Material.
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
WO1996028423A1 (fr) 1995-03-15 1996-09-19 Sankyo Company, Limited Composes dipeptidiques de structure ahpba
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2001036351A2 (en) * 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US7329782B2 (en) * 2001-06-12 2008-02-12 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1556085A4 (en) 2002-11-01 2012-08-22 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
JP4697962B2 (ja) * 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
PT1633340E (pt) * 2003-04-15 2011-02-22 Wellstat Therapeutics Corp Compostos para o tratamento de distúrbios metabólicos
WO2004098496A2 (en) 2003-04-30 2004-11-18 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20040242491A1 (en) * 2003-05-30 2004-12-02 Lytone Enterpprise Inc. Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide
WO2005115383A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
EP1657073B1 (en) * 2004-11-15 2008-02-27 The Pilot Ink Co., Ltd. Reversible thermochromic composition and microcapsules containing the same
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
UA95613C2 (ru) 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
KR20080086523A (ko) 2006-01-25 2008-09-25 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
WO2007117791A2 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
CN101466266A (zh) 2006-06-09 2009-06-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
AU2007285827A1 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
JP5496913B2 (ja) 2008-01-15 2014-05-21 ウェルスタット セラピューティクス コーポレイション 代謝異常の治療のための化合物
CN101969773B (zh) 2008-03-13 2015-08-19 维尔斯达医疗公司 用于降低尿酸的化合物和方法
US8410154B2 (en) 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid

Also Published As

Publication number Publication date
BRPI0924547B1 (pt) 2021-08-17
CN102976928A (zh) 2013-03-20
RU2501554C2 (ru) 2013-12-20
US9115072B2 (en) 2015-08-25
CN102976928B (zh) 2014-09-17
CA2716860C (en) 2017-08-29
JP2011515349A (ja) 2011-05-19
CA2716860A1 (en) 2009-12-17
EP3517109A1 (en) 2019-07-31
US20110014176A1 (en) 2011-01-20
BRPI0909299A2 (pt) 2014-02-04
WO2009151695A4 (en) 2010-03-04
ES2741153T3 (es) 2020-02-10
JP2012153690A (ja) 2012-08-16
EP2268141B1 (en) 2019-05-08
JP5547222B2 (ja) 2014-07-09
RU2010141823A (ru) 2012-04-20
NZ587433A (en) 2012-12-21
US20130259850A1 (en) 2013-10-03
WO2009151695A1 (en) 2009-12-17
BRPI0909299B1 (pt) 2021-11-23
AU2009258040B8 (en) 2014-04-24
DK2268141T3 (da) 2019-07-29
UA103894C2 (ru) 2013-12-10
IL247136B (en) 2018-06-28
NZ602321A (en) 2013-02-22
EP2268141A1 (en) 2011-01-05
RU2012110592A (ru) 2013-09-27
JP5339545B2 (ja) 2013-11-13
AU2009258040B2 (en) 2014-02-20
KR101677945B1 (ko) 2016-11-29
AU2009258040A1 (en) 2009-12-17
CN101969773B (zh) 2015-08-19
UA109638C2 (uk) 2015-09-25
KR101677944B1 (ko) 2016-11-21
RU2501555C2 (ru) 2013-12-20
IL208004A0 (en) 2010-12-30
KR20100127250A (ko) 2010-12-03
US8829058B2 (en) 2014-09-09
ZA201005872B (en) 2011-05-25
EP2268141A4 (en) 2011-09-14
CN101969773A (zh) 2011-02-09
MX342806B (es) 2016-10-13
BRPI0924547A2 (pt) 2015-06-23
AU2009258040A8 (en) 2014-04-24
KR20140119149A (ko) 2014-10-08
IL208004A (en) 2016-08-31

Similar Documents

Publication Publication Date Title
MX2010009959A (es) Compuestos y metodo para reducir el acido urico.
WO2009134995A3 (en) Tetrazole compounds for reducing uric acid
RU2012123155A (ru) Способы лечения синдрома дефицита внимания и гиперактивности
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
RU2488582C2 (ru) Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение
WO2007060257A3 (en) Diketopyrrolo-pyrrole compounds
JP2008525526A5 (es)
RU2010126056A (ru) Органические соединения
CO6261382A2 (es) Compuestos de imidazotiazol como moduladores de sirtuina
WO2007095174A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
UA105185C2 (uk) Піроли
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
WO2008108380A3 (en) Pyrrole compounds
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
TW200727893A (en) Methods for treating sexual dysfunction
NO20060502L (no) Forbindelser for behandling av metabolske forstyrrelser
MXPA05008600A (es) Compuestos para el tratamiento de desordenes metabolicos.
DE602004030004D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
MY151072A (en) Heteroaryl derivative
RU2013118021A (ru) Способы и композиции для лечения сахарного диабета и дислипидемии
WO2007096740A3 (en) Novel cephalosporins
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
TW200616679A (en) Modified-release preparation
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren

Legal Events

Date Code Title Description
FG Grant or registration